Evidence map›Paper›PMID 31978968›Full record

ReviewNanomaterials (Basel, Switzerland)2020

Immunological and Toxicological Considerations for the Design of Liposomes.

Collin T Inglut, Aaron J Sorrin, Thilinie Kuruppu, Shruti Vig, Julia Cicalo, Haroon Ahmad, Huang-Chiao Huang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 3 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 3 syntheses or guidelines pooled it, 347 citations in OpenAlex.

  1. Analyzing Molecular Determinants of Nanodrugs' Cytotoxic Effects.International journal of molecular sciences · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Method for Isolating Hypericin fromMolecules (Basel, Switzerland) · 2026
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Dichotomous role of CD47-SIRPActa pharmaceutica Sinica. B · 2026
    Article

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Collin T InglutFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Aaron J SorrinFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Thilinie KuruppuFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Shruti VigFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Julia CicaloFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Haroon AhmadMarlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Huang-Chiao HuangFischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
University of Maryland, College Park · USUniversity of Maryland, Baltimore · US

Funding

Multifunctional, GBM-Activatable Nanocarriers For Image-Guided PhotochemotherapyR00CA194269 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HUANG, HUANG CHIAO · 2018 to 2020
$701k
NCI NIH HHS R00 CA194269NCI NIH HHS R00CA194269
6 · The paper itself

Abstract

Liposomes hold great potential as gene and drug delivery vehicles due to their biocompatibility and modular properties, coupled with the major advantage of attenuating the risk of systemic toxicity from the encapsulated therapeutic agent. Decades of research have been dedicated to studying and optimizing liposomal formulations for a variety of medical applications, ranging from cancer therapeutics to analgesics. Some effort has also been made to elucidate the toxicities and immune responses that these drug formulations may elicit. Notably, intravenously injected liposomes can interact with plasma proteins, leading to opsonization, thereby altering the healthy cells they come into contact with during circulation and removal. Additionally, due to the pharmacokinetics of liposomes in circulation, drugs can end up sequestered in organs of the mononuclear phagocyte system, affecting liver and spleen function. Importantly, liposomal agents can also stimulate or suppress the immune system depending on their physiochemical properties, such as size, lipid composition, pegylation, and surface charge. Despite the surge in the clinical use of liposomal agents since 1995, there are still several drawbacks that limit their range of applications. This review presents a focused analysis of these limitations, with an emphasis on toxicity to healthy tissues and unfavorable immune responses, to shed light on key considerations that should be factored into the design and clinical use of liposomal formulations.

Indexed as

cancergene and drug deliveryimmunomodulationliposomestoxicity

Identifiers

PMID31978968
PMCPMC7074910
OpenAlexW3001824115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.